21 July 2024 : Clinical Research
Cost-Effectiveness Analysis of Hepatic Arterial Chemotherapy for Advanced Hepatocellular Carcinoma in China: A Comparative Analysis of HAIC-FO and Sorafenib
Jie Gao1BCE, Shu Liu2BCE, Shao-Jun Li1BCE, Rui Wang3E, Zeng-Hui Meng1AE, Xiang-Shuo Kong2AE*DOI: 10.12659/MSM.944526
Med Sci Monit 2024; 30:e944526
Table 3 Cost-effectiveness of treatment of HAIC-FO vs sorafenib in patients with high-risk factors.
| QALYs | Total cost, $ | ICER, $ (per QALY) | |
|---|---|---|---|
| Sorafenib | 0.49 | 13,885 | / |
| HAIC-FO | 0.96 | 19,612 | / |
| Incremental | 0.47 | 5,727 | 12,186 |
| HAIC-FO – hepatic arterial infusion chemotherapy with infusional fluorouracil, leucovorin, and oxaliplatin; QALYs – quality-adjusted life-years; ICER – incremental cost-effectiveness ratio. | |||